Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOptiBiotix Health Regulatory News (OPTI)

Share Price Information for OptiBiotix Health (OPTI)

Share Price is delayed by 15 minutes
Get Live Data
6.40    0.00 (0.00%)
Bid:
6.30
Ask:
6.50
Spread: 0.20 (3.175%)
Market Cap: £6.61m
OPTI Live PriceLast checked at - London Stock Exchange

Intraday OptiBiotix Health Share Chart

Half Yearly Results

18 Jul 2014 07:00

RNS Number : 6690M
Ducat Ventures PLC
18 July 2014
 



Ducat Ventures Plc ("Company")

 

Half Yearly Report

 

The Board of Ducat presents the unaudited historical financial information of the Company for the 6 months to 31 May 2014. 

 

Consolidated Statement of Comprehensive Income

For the six months ended 31 May 2014

 

 

 

 

Six months

 to 31 May

2014

Six months

 to 31 May

2013

 

 

 

(Unaudited)

(Unaudited)

Continuing operations

 

 

£

£

 

 

 

 

 

Revenue

 

 

-

-

Cost of Sales

 

 

-

-

 

 

 

───────

───────

 

 

 

 

 

Gross Loss

 

 

-

-

 

 

 

 

 

Administrative expenses

 

 

(57,643)

(166,453)

 

 

 

───────

───────

Operating Loss

 

 

(57,643)

(166,453)

 

 

 

 

 

Non Operating Items

 

 

 

 

Impairment of investments

 

 

-

(500,000)

Impairment of intercompany loans

 

 

-

(1,384,068)

Surplus arising on settlements with trade creditors

 

 

 

-

 

-

 

 

 

───────

───────

 

 

 

(57,643)

(2,050,521)

 

 

 

 

 

Finance Costs

 

 

-

-

 

 

 

───────

───────

Loss Before Tax

 

 

(57,643)

(2,050,521)

 

 

 

 

 

Taxation

 

 

-

-

 

 

 

───────

───────

Total comprehensive income for the period

 

 

 

(57,643)

 

(2,050,521)

 

 

 

═══════

═══════

 

 

 

 

 

Loss per share

 

 

0.006p

2.29p

 

 

 

═══════

═══════

 

 

 

 

 

 

 

 

Consolidated Balance Sheet

For the six months ended 31 May 2014

 

 

 

 

Six months

 to 31 May

2014

Six months

to 31 May

2013

 

 

 

(Unaudited)

(Unaudited)

ASSETS

 

 

£

£

 

 

 

 

 

 

 

 

 

 

CURRENT ASSETS

 

 

 

 

Trade and other receivables

 

 

10,034

49,077

Cash and cash equivalents

 

 

105,221

4,945

 

 

 

───────

───────

 

 

 

115,255

54,022

 

 

 

───────

───────

 

 

 

 

 

Total Assets

 

 

115,255

54,022

 

 

 

═══════

═══════

 

 

 

 

 

 

 

 

 

 

EQUITY

 

 

 

 

Shareholders' Equity

 

 

 

 

Called up share capital

 

 

5,742,586

5,636,083

Share premium

 

 

1,355,502

1,086,875

Share based payment reserve

 

 

27,200

27,200

Retained earnings

 

 

(7,013,950)

(6,830,754)

 

 

 

───────

───────

Total Equity

 

 

111,338

(80,596)

 

 

 

───────

───────

 

 

 

 

 

LIABILITIES

 

 

 

 

CURRENT LIABILITIES

 

 

 

 

 

 

 

 

 

Trade and other payables

 

 

3,917

134,618

 

 

 

───────

───────

 

 

 

3,917

134,618

 

 

 

───────

───────

Total Equity and Liabilities

 

 

115,255

54,022

 

 

 

══════

═══════

 

 

 

Consolidated statement of changes in equity

For the six months ended May 2014

 

 

 

 

Called up

Share

Capital

 

 

Share

Premium

Share-

Based

Payment

Reserve

 

 

Retained

Earnings

 

 

Total

Equity

 

£

£

£

£

£

 

 

 

 

 

 

Balance at 1 August 2012

5,574,070

838,822

27,200

(4,780,233)

1,659,859

 

 

 

 

 

 

Loss for period

-

-

-

(2,050,521)

(2,050,521)

 

 

 

 

 

 

Issue of shares

62,013

248,053

-

-

310,066

 

───────

──────

──────

───────

───────

Balance at 31 May 2013

5,636,083

1,086,875

27,200

(6,830,754)

(80,596)

 

 

 

 

 

 

Loss for the period

-

-

-

(125,553)

(125,553)

 

 

 

 

 

 

Issue of shares

86,165

215,936

-

-

302,101

 

───────

──────

──────

───────

───────

Balance at 30 November 2013

5,722,248

1,302,811

27,200

(6,956,307)

95,952

 

 

 

 

 

 

Loss for the period

-

-

-

(57,643)

(57,643)

 

 

 

 

 

 

Issue of ordinary shares at £0.0004 per shares less cost

 

20,338

 

52,691

-

 

 

-

 

73,029

 

───────

──────

──────

───────

───────

Balance at 31 May 2014

5,742,586

1,355,502

27,200

(7,013,950)

113,338

 

══════

══════

══════

══════

═══════

 

 

Consolidated Statement of Cash Flows

As at 31 May 2014

 

 

 

 

 

Six months

 to 31 May

2014

Six months 

to 31 May

2013

 

 

(Unaudited)

(Unaudited)

 

 

£

£

 

 

 

 

Cash flows from operating activities

 

 

 

Loss before tax

 

(57,643)

(166,453)

(Increase)/decrease in trade and other

 receivables

 

 

291,233

 

(81,262)

Increase)/decrease in trade and other

payables

 

 

(201,548)

 

(57,416)

 

 

───────

───────

Net cash from operating activities

 

32,042

(305,131)

 

 

───────

───────

 

 

 

 

 

 

 

 

Cash flows from financing activities

 

 

 

Issue of equity net of costs

 

73,029

310,067

Finance interest paid

 

-

-

 

 

───────

───────

Net cash from financing activities

 

73,029

310,067

 

 

───────

───────

 

 

 

 

Increase/(decrease) in cash and cash

equivalents

 

 

105,071

 

4,936

 

 

 

 

Cash and cash equivalents at the beginning of period

 

 

150

 

9

 

 

───────

───────

Cash and cash equivalents at the end of period

 

 

105,221

 

4,945

 

 

══════

═══════

 

 

 

 

 

Enquiries:

 

For further information, please contact:

Ducat Ventures plc

Nicholas Nelson

07921 522 920

Cairn Financial Advisers LLP

Liam Murray / Avi Robinson

020 7148 7900

Peterhouse Corporate Finance Ltd

Lucy Williams/ Duncan Vasey

020 7469 0936

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IR FMGMNVNFGDZM
Date   Source Headline
10th Jun 20197:00 amRNSLicense agreement for CholBiome® in Vietnam
29th May 20193:17 pmRNSDirector's Dealing
28th May 20197:00 amRNSAppointment of CEO of ProBiotix Health
22nd May 20197:00 amRNSGoFigure® distribution agreement for Poland
20th May 20197:00 amRNSLicense agreement for LPLDL®
17th May 20197:00 amRNSNotice of AGM
14th May 20197:00 amRNSDistribution Agreement for SlimBiome® in Thailand
7th May 20197:00 amRNSLicense agreement for LPLDL®
2nd May 20197:00 amRNSInvestor evening
1st May 20197:00 amRNSSlimBiome launch to EU market at Vitafoods Europe
29th Apr 20197:00 amRNSFinal Results
24th Apr 20197:00 amRNSSlimBiome® Medical launches in UK market
11th Apr 20197:00 amRNSSlimBiome® receives approval from FSSAI in India
9th Apr 20197:00 amRNSSlimBiome® Medical agreement for Bulgaria
27th Mar 20193:18 pmRNSGrant of Options
27th Mar 20197:43 amRNSSweetBiotix®: Scientific and commercial update
27th Mar 20197:00 amRNSSweetBiotix®: Scientific and commercial update
25th Mar 201911:00 amRNSPrice Monitoring Extension
20th Mar 20197:00 amRNSExclusive distribution agreement for SlimBiome®
15th Mar 20197:00 amRNSExtension of term and territories for LPLDL®
13th Mar 20193:42 pmRNSExercise of Warrants
21st Feb 20197:00 amRNSLPLDL® determined GRAS by an Expert Panel in US
20th Feb 20197:00 amRNSPresentations at ProBiota - 2019
13th Feb 20197:00 amRNSTrading Statement
11th Feb 20197:00 amRNSDistribution agreement for LPLDL® in Japan
7th Feb 20197:00 amRNSSupply agreement for LPLDL® in the Baltic States
18th Jan 20191:56 pmRNSExercise of Warrants
11th Jan 20197:00 amRNSDirector Appointment
9th Jan 20197:00 amRNSDistribution agreement for CholBiome
7th Jan 20197:00 amRNSManufacturing agreement for SlimBiome®
17th Dec 20187:00 amRNSDirectorate Change
14th Dec 20187:00 amRNSIssue of Convertible Loan Notes by ProBiotix
5th Dec 20182:58 pmRNSHolding(s) in Company
4th Dec 20187:00 amRNSSlImBiome® Medical agreement for Greece and Cyprus
29th Nov 20187:00 amRNSSlimBiome Medical manufacturing agreement
27th Nov 20187:00 amRNSSlimBiome® granted medical device status & CE mark
22nd Nov 20187:00 amRNSCholBiome® agreement for Greece and Cyprus
11th Oct 20187:00 amRNSDirector's Dealing
9th Oct 20187:00 amRNSLPLDL® US manufacturing and supply agreement
8th Oct 20187:00 amRNSExercise of Options & Director's Dealing
3rd Oct 20187:00 amRNSNon-exclusive distribution agreement for SlimBiome
1st Oct 20187:00 amRNSNon-exclusive distribution agreement for SlimBiome
26th Sep 20187:00 amRNSDistribution agreement for CholBiome®
25th Sep 20187:00 amRNSDirector/PDMR Shareholding
24th Sep 20187:00 amRNSFormation of ProBiotix Health Limited
10th Sep 20187:00 amRNSDirector Appointment
10th Sep 20187:00 amRNSLicence agreement with Bened Biomedical
10th Sep 20187:00 amRNSExercise of Warrants and Issue of Equity
4th Sep 20187:00 amRNSOptiBiotix signs US pharmaceutical deal
30th Aug 20187:00 amRNSHalf-year Report

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.